Ilvisinus (Pseudoephedrine Hydrochloride, Ibuprofen)

Pseudoephedrine acts as an alpha‑adrenergic agonist, causing the blood vessels in the nasal mucosa to constrict. This vasoconstriction reduces swelling and edema, opening the airway and improving breathing when a person is congested.

The appropriate dose of Ilvisinus is determined by the prescribing healthcare professional based on the individual’s age, weight, medical condition and other medications. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Ilvisinus.

To request Ilvisinus, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ilvisinus combines two well‑established agents—pseudoephedrine for decongestion and ibuprofen for analgesia/anti‑inflammation—into a single tablet, which can simplify dosing compared with taking separate products. Its dual action may provide faster symptom relief, but the safety profile reflects the combined effects of both classes.

Ilvisinus should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Ilvisinus is taken orally with a full glass of water. It is usually swallowed whole and not chewed or crushed, unless a healthcare professional advises otherwise. The tablet should be taken with or without food as directed by the prescriber.

Serious risks include severe allergic reactions (anaphylaxis), significant elevation of blood pressure, gastrointestinal bleeding, liver enzyme abnormalities, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms such as rash, swelling, difficulty breathing, chest pain, or vomiting blood.

Ilvisinus should be avoided by individuals with uncontrolled hypertension, severe cardiovascular disease, known hypersensitivity to pseudoephedrine, ibuprofen or any component of the formulation, and those taking monoamine oxidase inhibitors. It is also contraindicated in patients with active peptic ulcer disease or significant renal or hepatic impairment unless advised by a physician.